NANJING, China, May 9, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (“Simcere” or the “Company”) (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, announced today that the Company filed its annual report on Form 20-F for the year ended December 31, 2010 with the Securities and Exchange Commission on May 9, 2011. The annual report can be accessed on the Company’s investor relations website at http://ir.simcere.com. The Company will provide a hard copy of the annual report containing its audited financial statements for the year ended December 31, 2010, free of charge, to its shareholders and ADS holders upon request.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (“Simcere”) (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts: | |
Email: ir@simcere.com | |
In Nanjing: | |
Yehong Zhang | |
President | |
Simcere Pharmaceutical Group | |
Tel: +86-25-8556-6666 ext 8811 | |
In Beijing: | |
Yue Yu | |
Brunswick Group | |
Tel: +86-10-5960-8600 | |
In the United States: | |
Kate Tellier | |
Brunswick Group | |
Tel: +1-212-333-3810 | |
In Hong Kong: | |
Joseph Lo Chi-Lun | |
Brunswick Group | |
Tel: +852-3512-5000 | |
SOURCE Simcere Pharmaceutical Group
